Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 2/2004

01-02-2004 | Case Report

Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma

Authors: A. Yokohama, N. Tsukamoto, H. Uchiumi, H. Handa, T. Matsushima, M. Karasawa, H. Murakami, Y. Nojima

Published in: Annals of Hematology | Issue 2/2004

Login to get access

Abstract

We describe a 65-year-old man diagnosed with Burkitt's lymphoma arising from the intestine. The tumor cells had a mature B-cell immunophenotype and rearrangement of the c-myc gene. The patient was treated with intensive multiagent chemotherapy. After four courses of chemotherapy, an ileus developed due to a residual abdominal disease. We administered rituximab in combination with the same chemotherapy regimen. A dramatic clinical improvement was observed and abnormal uptake by 18F-fluorodeoxyglucose positron emission tomography disappeared. The patient experienced complete remission for 1 year. This encouraging result indicates that rituximab might be an important treatment choice in management of Burkitt's lymphoma.
Literature
1.
Hecht J, Aster J (2000) Molecular biology of Burkitt's lymphoma. J Clin Oncol 18:3707–3721PubMed
2.
Magrath I, Adde M, Shad A, et al. (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925–934PubMed
3.
Patte C, Philip T, Rodary C, et al. (1991) High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123–132PubMed
4.
Patte C, Auperin A, Michon J, et al. (2001) The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379CrossRefPubMed
5.
Soussain C, Patte C, Ostronoff M, et al. (1995) Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85:664–674PubMed
6.
Mead G, Sydes M, Walewski J, et al. (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264–1274CrossRefPubMed
7.
Lee E, Petroni G, Schiffer C, et al. (2001) Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 19:4014–4022PubMed
8.
Maloney D, Grillo-Lopez A, White C, et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188–2195PubMed
9.
Hainsworth J, Burris III H, Morrissey L, et al. (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052–3056PubMed
10.
Czuczman MS, Grillo-Lopez AJ, White CA, et al. (1999) Treatment of patients with low-grade B-cell Lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276PubMed
11.
Coiffier B, Lepage E, Briere J, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242PubMed
12.
Thomas D, Cortes J, Giles F, et al. (2001) Rituximab and hyper-CVAD for adult Burkitt's (BL) or Burkitt's-like (BLL) leukemia or lymphoma. Blood 98:804a
13.
Cohen Y, Amir G, Rachmilewitz E, et al. (2002) Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma. Hematologica 87:ETL04
14.
McGuirk JP, Dix SP, Belt RJ (2000) Rituximab and immune modulation post unrelated donor transplantation as treatment for refractory Burkitt's-like lymphoma (abstract 4775). Blood 96:242b
15.
Akasaka T, Muramatsu M, Ohno H, et al. (1996) Application of long-distance polymerase chain reaction to detection of junctional sequence created by chromosomal translocation in mature B-cell neoplasms. Blood 88:985–994PubMed
16.
Reiter A, Schrappe M, Tiemann M, et al. (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group trial NHL-BFM90. Blood 94:3294-3306PubMed
17.
Vose J, Link B, Grossbard M, et al. (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389–397PubMed
Metadata
Title
Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma
Authors
A. Yokohama
N. Tsukamoto
H. Uchiumi
H. Handa
T. Matsushima
M. Karasawa
H. Murakami
Y. Nojima
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 2/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0758-2

Other articles of this Issue 2/2004

Annals of Hematology 2/2004 Go to the issue

Original Article

Early and late gastrointestinal complications after myeloablative and nonmyeloablative allogeneic stem cell transplantation

Case Report

Successful treatment with rituximab for autoimmune hemolytic anemia concomitant with proliferation of Epstein-Barr virus and monoclonal gammopathy in a post-nonmyeloablative stem cell transplant patient

Case Report

Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab

Case Report

Clonal relationship in multifocal non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue (MALT)

Original Article

Evaluation of serum ferritin in screening for iron deficiency in tuberculosis

Original Article

Presentation assessment of minor histocompatibility antigens by predictive proteasomal cleavage analysis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits